Protocols
5 protocol(s) meet the specified criteria
Drug: DAUNORUBICIN
Protocol No.TitleStatus
CALGB10403An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia (ALL)Open (affiliates only)
CALGB10503Phase II Study of Maintenance Therapy with Decitabine (NSC #127716, IND #50733) Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients with AML < 60 YearsOpen (affiliates only)
CALGB10603A Phase III Randomized, Double-Blind Study Of Induction (Daunorubicin/Cytarabine) And Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (Pkc412) (Ind #101261) Or Placebo In Newly Diagnosed Patients < 60 Years Of Age With FLT3 Mutated Acute Myeloid Leukemia (AML)Open (affiliates only)
COGAAML1031A Phase III Randomized Trial for Patients with de novo AML using Bortezomib(IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITDOpen
E1910A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults.Open